Carbohydrates Distribution in Pregnancy Study
- Conditions
- Gestational Diabetes Mellitus in Pregnancy
- Interventions
- Behavioral: Intervention Treatment
- Registration Number
- NCT03378908
- Lead Sponsor
- Germans Trias i Pujol Hospital
- Brief Summary
Hypothesis: Patients with Gestational Diabetes Mellitus (GDM) have a high risk to develop complications during pregnancy, puerperium and in the newborn. At present there are not scientific evidences about the optimal distribution of meals in the medical nutrition therapy (MNT) and their relationship with glycemic control.
Aim: To explore and compare ketonemia and glycemic profile in patients with GDM that follow a MNT distributed in 6 or 3 meals. Besides, we want to explore the differences between both treatments in glucose dynamics.
Methods: The study design is a randomized, crossover and multicentric trial. A sample of 10 patients with GDM will be recruited in the Department of Endocrinology and Nutrition from both centres. In a randomized manner patients will follow the conventional treatment (a carbohydrate-controlled diet distributed in 6 meals: 3 main meals and 3 snacks) and the intervention treatment (a carbohydrate-controlled diet distributed in 3 meals: breakfast, lunch and dinner). They will be randomized to begin with one of the two treatments, and after two weeks they will be switched to the other treatment. Patients will wear a blinded continuous glucose monitoring device (iPro2-TM, Medtronic) during the entire study period.
Inclusion criteria:
* Women with GDM diagnosed in 24-28 weeks.
* Age 18-40 years.
* Pregnancy age of 28-32 weeks.
* Caucasian.
* Body mass index ≤ 35 Kg/m2.
Exclusion criteria:
* Unability to understand the dietary recommendations and/or to perform self-management of glycemia, ketonuria or ketonemia.
* A low adherence to MNT.
* Problems with written and/or oral communication.
* Presence of comorbidities other than obesity, hypertension and dyslipidemia.
* Insulin-need criteria within 3 first days of the beginning of the study (fasting glucose ≥90mg/dL, postprandial glucose 1-hour ≥140mg/dL).
Clinical and sociodemographic variables will be assessed. Dietary records and blood samples will be collected. Daily basal ketonuria and ketonemia before each meal will be assessed. Glycemic profile will be collected with a blind-sensor during the four weeks of the intervention study. Generalized linear model analysis will be performed. Statistical power will be 80% and significance level will be set at 0.05. Written informed consent will be collected from all participants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 10
- Women with GDM diagnosed in 24-28 weeks.
- Age 18-40 years.
- Pregnancy age of 28-32 weeks.
- Caucasian.
- Body mass index ≤ 35Kg/m2.
- Firs-time mother.
- Disability to understand the dietary recommendations and/or to perform self-management of glycemia, ketonuria or ketonemia.
- A low adherence to MNT.
- Problems with write and oral communication.
- Other comorbidities differed of obesity, hypertension and dyslipidemia.
- Insulin criteria within 3 first days of study (fasting glucose ≥90mg/dL, postprandial glucose 1-hour ≥140mg/dL).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Intervention Treatment 3 meals Intervention Treatment Diet will be distributed in 3 meals (breakfast, lunch and dinner). Each meal will consist of the addition of the conventional meal and the next snack. Energy intake will be distributed: 30% breakfast (25% breakfast + 5% snack), 40% lunch (30% lunch + 10% snack) and 30% dinner (25% dinner and 5% snack).
- Primary Outcome Measures
Name Time Method Preprandial ketonemia 4 weeks (2 weeks with the conventional treatment and 2 weeks with the intervention treatment) Before the 3 main meals every day.
Glycemic profile below pregnancy target capillary blood glucose concentration 4 weeks (2 weeks with conventional treatment and 2 weeks with intervention treatment) Self monitoring blood glucose levels: pre meals \< 90 mg/dL, 1 hour post meals \<140mg/dL
- Secondary Outcome Measures
Name Time Method Newborn hypoglycemia 48 hours from delivery Serum glycemia \<40 mg/dL in the first 48 hours of life
Postpartum glucose tolerance of the mother 6 weeks after delivery Plasma glucose levels fasting and 120 minutes after a 75 g oral glucose load
Area under the curve of interstitial glucose levels Time Frame: 4 weeks (2 weeks with conventional treatment and 2 weeks with intervention treatment) Blinded continuous glucose monitoring data, iPro2, Medtronic (r)): diurnal (from 7 am to 11 pm) and nocturnal (from 11pm to 7 am)
Fetal Macrosomia Through study completion, 4 weeks US assessed fetal weight, adjusted for national standardized charts
Newborn body weight adjusted for gestational age (national standardized charts) At delivery Large for gestational age \> 90th centile, small for gestational age \< 10th centile
Point-of-care glycated hemoglobin (HbA1c) Every 2 weeks from the date of randomization until the last visit of the study DCA Vantage Analyzer, Siemens ®
Trial Locations
- Locations (2)
Marta Hernández
🇪🇸Lleida, Spain
Berta Soldevila
🇪🇸Badalona, Barcelona, Spain